bullish
Revisiting the Bristol-Myers Squibb (BMY US) Bullish Investment Thesis After the Q3 Earnings Report.
390 Views02 Nov 2016 08:31
In our first report on Bristol Myers Squibb Co (BMY US), we presented our bullish contrarian thesis and considered the common stock undervalued for...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Revisiting the Bristol-Myers Squibb (BMY US) Bullish Investment Thesis After the Q3 Earnings Report.02 Nov 2016
- Could Blue-Chip Bristol-Myers Squibb's (NYSE: BMY) Shares Rise More than 40% by Early 2018?18 Oct 2016
x